TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study
The purpose of this post-authorisation medical device study is to obtain real life data on the use of Tumor Treating Fields (TTFields) in patients with pleural mesothelioma in routine clinical care. Patients with pleural mesothelioma and clinical indication for TTFields treatment will be enrolled in the study after signing Informed consent to use their data and process it centrally for research purposes. The clinical indication for TTFields is one of the inclusion criteria and is defined prior to inclusion by the treating physician.
Pleural Mesothelioma
DEVICE: TTFields
Time from diagnosis of pleural mesothelioma to death of any cause as median overall survival time., 54 Months
Number of TTFields treatment-related SAEs, as assessed by the CEC, within total observation period, standardized to average annual incidences., 3 years + 18 months follow up|Changes in quality of life comparing baseline with 3 and 6 months after start of TTFields therapy., QoL will be assessed at baseline, 3 and 6 months.
The purpose of this post-authorisation medical device study is to obtain real life data on the use of Tumor Treating Fields (TTFields) in patients with pleural mesothelioma in routine clinical care. Patients with pleural mesothelioma and clinical indication for TTFields treatment will be enrolled in the study after signing Informed consent to use their data and process it centrally for research purposes. The clinical indication for TTFields is one of the inclusion criteria and is defined prior to inclusion by the treating physician.